This review summarizes the latest updates on using antiandrogens as potential prophylactic and therapeutic options for COVID-19, highlighting that androgen-mediated regulation of factors like TMPRSS2 and ACE2 is involved in SARS-CoV-2 infection, suggesting a strategy to block viral entry into cells.
18 citations
,
June 2021 in “Endocrinology” This review discusses the link between androgen receptor action and TMPRSS2 expression in severe COVID-19, exploring the potential of anti-androgens to mitigate disease severity in men and notes ongoing trials.
3 citations
,
December 2020 in “Problemy e̊ndokrinologii” This review discusses androgen and antiandrogen studies in COVID-19, noting potential impacts on disease severity and suggesting the need for more data on their effectiveness and safety.
31 citations
,
September 2020 in “Clinical endocrinology” This review found limited evidence on the effectiveness of different antiandrogens for feminization in transgender women, suggesting cyproterone acetate, leuprolide, and medroxyprogesterone acetate may better suppress testosterone than spironolactone or estradiol alone.
110 citations
,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.
24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
124 citations
,
January 1993 in “The Prostate” Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
